LONPOVAMERAN
UNII UY3ACU236M

Substance Identification & Data

This profile provides standardized clinical and technical data for Lonpovameran, uniquely identified by the FDA Unique Ingredient Identifier (UNII) UY3ACU236M.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2972476-18-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

UY3ACU236M

CAS Registry Number

2972476-18-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LONPOVAMERAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C211813

National Cancer Institute reference terminology for clinical and research data.

INN ID

13556

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

nucleicAcid

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Lonpovameran. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LONPOVAMERAN

Common Names & Synonyms

LONPOVAMERAN [INN]

RNA (RECOMBINANT 5'-(M7G-(5'->5')-PPP-AM)-CAPPED VENEZUELAN EQUINE ENCEPHALITIS VIRUS NONSTRUCTURAL PROTEINS NSP1, NSP2 (739-LEUCINE), NSP3 (ENDO-551A-ARGININE) AND NSP4 (RNA-DEPENDENT RNA POLYMERASE) CODON-OPTIMIZED TRANSGENE PLUS SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN (682-GLYCINE,683-SERINE,685-SERINE,986-PROLINE,987-PROLINE) OMICRON XBB.1.5 VARIANT PRECURSOR-SPECIFYING PLUS 5'-AND 3'-UNTRANSLATED FLANKING REGION-CONTAINING POLY(A)-TAILED MESSENGER MRNA-2319), INNER SALT

SELF-AMPLIFYING MESSENGER RNA (MRNA), 5'-CAPPED, ENCODING CODON-OPTIMISED VENEZUELAN EQUINE ENCEPHALITIS VIRUS (VEEV) RNA-DEPENDENT RNA POLYMERASE (VEEV PROTEINS NSP1, NSP2, NSP3 AND NSP4) AND A FULL-LENGTH CODON-OPTIMISED PRE-FUSION STABILISED CONFORMATION VARIANT (K982P AND V983P) OF THE SARS-COV-2 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2) SPIKE (S) GLYCOPROTEIN XBB.1.5 VARIANT (DERIVED FROM GENBANK ID: UZG29433.1) CONTAINING FURIN CLEAVAGE-INACTIVATING MUTATIONS (R678G, R679S AND R681S), FLANKED BY 5' AND 3' UNTRANSLATED REGIONS AND A 3' POLYADENYLATION (POLYA) TAIL; GENERATION OF CAPPED S GLYCOPROTEIN MRNA IS UNDER CONTROL OF A VEEV SUBGENOMIC PROMOTER

Technical Codes

MRNA-2319

External Clinical & Regulatory Resources

Previous UNIIUY37U9SN2M

Next UNIIUY3TW7VRW9